… EGFR-mutations in this study actually had poorer outcomes with gefitinib (hazard ratio for …
than erlotinib, further information is needed pertaining to osimertinib. Thirdly, our study has not …

… All of these studies comprised independent cohorts (separate … Gefitinib monotherapy is also
widely used currently. In a phase III trial comparing erlotinib with gefitinib, the erlotinib group …

… EGFR-TKI chemotherapy, that is gefitinib or erlotinib; data were censored at the date of … , or
the end of the study, ie December 31, 2013. We ascertained the study outcomes using HWDS …

… In this study, osimertinib 160 mg was also effective and safe. It showed a 62% ORR and
a … Thus, we conducted this phase II, prospective, two cohort study using a double dose of …

… Erlotinib was dominantly used, and first-generation EGFR-TKI composed of erlotinib and
gefitinib was frequently used in 53 cohorts. Detailed characteristics of 53 eligible cohorts were …

… first-generation EGFR TKIs (eg, gefitinib and erlotinib) is approximately 10 to 12 months.10, …
, is a superior first-line therapy according to the FLAURA study, 11 , 12 there is no standard …

… This large cohort study confirms the substantial interindividual variability in erlotinib plasma
… This large variability in erlotinib pharmacokinetics indicates that the standard recommended …

… In this population-based retrospective cohort study, we … our study cohort, including 6230
(59.7%) receiving gefitinib, … ; the number of gefitinib users decreased after erlotinib and afatinib …

… Forty-six patients with 64 lung lesions treated with at least 8 weeks of TKIs (erlotinib, gefitinib,
… Using PSM with a ratio of 1:2, the study cohort was composed of 45 patients treated with …

… Despite the positive results of tepotinib plus gefitinib in patients with MET amplification as …
limitation of this study was the poor recruitment, resulting in early termination of the study with a …